GlassScriptPhysician profile
Geoffrey L Whitley
NPI 1083994404
$65,586.13
in general payments reported to CMS, 2019-2025
24 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,523 · 2022: $20K · 2023: $9,675 · 2024: $20K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $15K · Honoraria: $6,988 · Travel and Lodging: $2,142 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,789.00 |
| Food and Beverage | $14,672.97 |
| Honoraria | $6,988.00 |
| Travel and Lodging | $2,141.66 |
| Education | $119.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $28,609.85 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $14,101.07 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $4,101.29 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,984.43 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $2,389.72 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $2,261.54 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $2,159.68 | 2022-2025 | Ingrezza |
| Corium, LLC | $1,900.14 | 2022-2024 | Azstarys |
| Lundbeck LLC | $1,651.47 | 2021-2025 | Rexulti, Brintellix |
| Otsuka America Pharmaceutical, INC. | $1,485.49 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $1,182.53 | 2023-2025 | Qelbree, Oxtellar Xr |
| Teva Pharmaceuticals USA, INC. | $853.92 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $273.01 | 2024-2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $154.93 | 2022 | |
| Tris Pharma INC | $95.10 | 2023-2025 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $93.32 | 2022 | |
| Harmony Biosciences LLC | $62.69 | 2025 | |
| Vanda Pharmaceuticals INC. | $58.25 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $37.62 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $30.47 | 2023 | Quviviq |
| Indivior INC. | $29.79 | 2024 | Sublocade |
| Alfasigma USA, INC. | $25.93 | 2022 | |
| Ironshore Pharmaceuticals INC. | $24.15 | 2023 | Jornay Pm |
| Eisai INC. | $19.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Whitley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.